title: Monoclonal antibody strategies to block angiogenesis.
abstract: Antibodies represent a unique class of therapeutics because of their high specificity towards a defined target antigen. Recent clinical success with antibody-based cancer therapeutics has led to an increase in the clinical development of these agents. Antibody therapeutics offer a promising approach for inhibiting new blood vessel formation (angiogenesis), which is associated with a variety of diseases, including cancer. In this review we will focus on angiogenesis-related mechanisms targeted by antibody-based therapeutics, with an emphasis on those studies where pre-clinical in vivo data is available.
authors.affiliation: ImClone Systems, 180 Varick Street, 10014, New York, NY, USA
authors.forename: D J.
authors.initials: DJ
authors.lastname: Hicklin
authors.forename: L
authors.initials: L
authors.lastname: Witte
authors.forename: Z
authors.initials: Z
authors.lastname: Zhu
authors.forename: F
authors.initials: F
authors.lastname: Liao
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: P
authors.initials: P
authors.lastname: Bohlen